Printer Friendly

Grifols shares gain 42.65% since Jan 2011.

M2 PHARMA-July 19, 2011-Grifols shares gain 42.65% since Jan 2011(C)2011 M2 COMMUNICATIONS

19 July 2011 - Spain-based biopharmaceutical group Grifols (MCE: GRF) has gained 42.65% since the beginning of the year and thus became the only firm of the blue-chip index IBEX 35 trading in the black in July.

Yesterday, the company closed with a 1.29% rise to EUR14.55 - its highest price since October 2008. Grifols has won 5.13% so far in July while the index has dipped by 9.77%.

The acquisition of US Talecris Biotherapeutics (NASDAQ:TLCR) for EUR2.8bn (USD3.94bn) made Grifols a relevant international player with a revenue of over EUR2bn. The geographic diversification of the Spanish company was welcomed by the investors. Grifols' business depend only at 10% on the Spanish market, while the USA share in the total revenue will rise to 53% from 34% after the acquisition.

The market consensus is giving a 5% upside potential to Grifols on the Madrid stock exchange, according to data of Bloomberg. Around 60% of the analysts gave "buy" recommendation.

(EUR1 = USD1.408)

((Comments on this story may be sent to

COPYRIGHT 2011 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jul 19, 2011
Previous Article:Sonova names Lukas Braunschweiler CEO.
Next Article:Luminex gets FDA nod for respiratory viral panel test FAST.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters